The present invention generally relates to use of
single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-
thio-
cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases.More particularly, the present invention relates to isomer-pure,
single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-
cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-
cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin
sodium salts in medication used for the prevention or treatment of lysosomal storage diseases.